Clinical Trials

List clinical trials by disease

The results of your search are listed below. To view the details of a trial or study, click on the "see details >" link. Or start a new search.

Searched for: Ovarian Cancer. 8 results shown below.

A Phase 1 Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women

[Complete title: A Randomized Controlled Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women (Novel Markers Trial)]
Principal Investigator: Nicole Urban, Sc.D., ScD
Study Number: 6973
Phase: I

Memory and Thinking Skills Workshop in Improving Cognitive Rehabilitation in Gynecologic and Breast Cancer Survivors

[Complete title: Behavioral and Neural Indices of Cognitive Rehabilitation in Women's Cancer: A Pilot Study]
Principal Investigator: Heidi Gray, MD
Study Number: 7750
Phase: Pilot

A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination with Bevacizumab (NSC#704865, IND #113912) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer
Principal Investigator: Heidi Gray, MD
Study Number: GOG 0213
Phase: II/III

Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

[Complete title: A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer]
Principal Investigator: Heidi Gray, MD
Study Number: GOG 0260
Phase: II

MSB0010718C in Solid Tumors

[Complete title: A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications]
Principal Investigator: Nora Disis, MD
Study Number: 20132079
Phase: I

A Study Of PF-06664178 In Patients With Advanced Solid Tumors

[Complete title: A Phase 1, Dose Escalation Study of PF-06664178 in Patients with Locally Advanced or Metastatic Solid Tumors]
Principal Investigator: Keith Eaton, MD, PhD
Study Number: 20141074
Phase: I

A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1

[Complete title: A Phase 1, Open-Label Clinical Trial Evaluating the Safety, Tolerability and Immunogenicity of Intradermally Administered ID-LV305 in Patients with Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1 20140453]
Principal Investigator: Seth Pollack
Study Number: 9079
Phase: I

A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)

[Complete title: A Phase 2, Open-Label Study of Rucaparib in Patients with Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer]
Principal Investigator: Elizabeth Swisher, MD
Study Number: CO-338-017
Phase: II

Select a disease from the list below:

Limit results to studies enrolling:

OR

Search by Keyword, Investigator Name or Study ID#:

Limit results to studies enrolling:

OR

View all studies

Limit results to studies enrolling:

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials